View company's website
4 known investors
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.
BiotechHealthtechMedical Devices